<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01763346</url>
  </required_header>
  <id_info>
    <org_study_id>BETAFAT</org_study_id>
    <secondary_id>U01DK094430</secondary_id>
    <secondary_id>IIT - 000395</secondary_id>
    <nct_id>NCT01763346</nct_id>
  </id_info>
  <brief_title>Beta Cell Restoration Through Fat Mitigation</brief_title>
  <acronym>BetaFat</acronym>
  <official_title>Beta Cell Restoration Through Fat Mitigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Weight loss achieved through gastric banding will be superior to treatment with metformin in
      preserving or restoring pancreatic beta cell function in people with prediabetes or mild type
      2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BetaFat is a 2-arm, unblinded study to compare gastric banding to treatment with metformin
      over a 24-month period in moderately obese adults with pre- or mild type 2 diabetes. The
      primary outcome will be change in β-cell compensation for insulin resistance, which the
      investigators will compare between groups. Secondary analyses will include other potential
      markers of β-cell health and potential mediators of treatment-specific effects. The main
      focus will be on mediators related to obesity. Clinically, the project will serve as a test
      of concept for use of gastric banding relatively early in the spectrum of obesity and β-cell
      disease. Biologically, the results will provide crucial information on potential mediators of
      β-cell failure and its arrest or reversal in the context of obesity. Those mediators will
      guide the development of more effective treatment and monitoring for the β-cell disease that
      causes type 2 diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady State Beta Cell Compensation</measure>
    <time_frame>24 months</time_frame>
    <description>mean plasma C-peptide concentration during clamp steady state, adjusted for mean clamp insulin sensitivity</description>
  </primary_outcome>
  <other_outcome>
    <measure>Glycemia</measure>
    <time_frame>24 months</time_frame>
    <description>fasting and 2-hour OGTT glucose levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Glycemia</measure>
    <time_frame>24 months</time_frame>
    <description>HbA1C</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Prediabetes</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects receiving metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gastric banding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects receiving LAP-BAND</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>metformin 1000 mg bid</description>
    <arm_group_label>metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>gastric banding</intervention_name>
    <description>LAP-BAND</description>
    <arm_group_label>gastric banding</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Prior completion of at least two months in a diet, exercise and lifestyle intervention
             program within the past two years

          2. Fasting plasma glucose &gt;90 mg/dl plus 2-hour glucose ≥140 mg/dl on 75 gm OGTT plus
             HbA1C ≤7.0%. There is no lower limit for the A1C and no upper limit for the OGTT
             2-hour glucose based on prior studies that allow us to identify people with falling
             β-cell function

          3. Age 22-65 years

          4. Body mass index (BMI) 30-40 kg/m2

          5. For participants with diabetes, known duration &lt;1 year

          6. No history of use of antidiabetic medications except during pregnancy

        Exclusion Criteria:

          1. Contraindications to LapBand(see Appendix 1)

          2. Contraindication to MRI (claustrophobia; permanent metal objects such as pacemakers,
             prostheses, aneurysm clips)

          3. Underlying disease(s) likely to (a) limit life span to less than study duration and/or
             (b) increase risk of intervention outside of the study and/or (c) limit ability to
             participate in outcomes assessment and/or (d) limit participation

          4. An underlying disease known to have important effects on glucose metabolism

          5. Active infections

          6. Renal disease (serum creatinine ≥1.4 mg/dl for men; ≥1.3 mg/dl for women) or serum
             potassium abnormality (&lt;3.4 or &gt;5.5 mmol/l)

          7. Anemia (hemoglobin &lt;11g/dl in women, &lt;12 g/dl in men) or known coagulopathy

          8. Cardiovascular disease, including uncontrolled hypertension and symptomatic congestive
             heart failure. Participants must be able to safely tolerate administration of
             fluid/volume challenges during clamp studies.

          9. Serum AST &gt;3 times upper limit of normal in local clinical lab

         10. Excessive alcohol intake

         11. Suboptimally treated thyroid disease

         12. Conditions or behaviors likely to affect the conduct of the study

               1. unable or unwilling to give informed consent

               2. unable to adequately communicate with clinic staff

               3. another household member is a participant or staff member

               4. current or anticipated participation in another intervention research project
                  that would interfere with any of the interventions/outcomes

               5. likely to move away from participating clinic in next 2 years

               6. current (or anticipated) pregnancy and lactation.

               7. major psychiatric disorder that, in the opinion of clinic staff, would impede the
                  conduct of the study

               8. weight loss &gt;5% in past three months for any reason except postpartum weight
                  loss.

         13. additional conditions may serve as criteria for exclusion at the discretion of the
             local site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas A Buchanan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>91011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>RISE Consortium. Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care. 2014;37(3):780-8. doi: 10.2337/dc13-1879. Epub 2013 Nov 5.</citation>
    <PMID>24194506</PMID>
  </reference>
  <results_reference>
    <citation>Xiang AH, Trigo E, Martinez M, Katkhouda N, Beale E, Wang X, Wu J, Chow T, Montgomery C, Nayak KS, Hendee F, Buchanan TA; RISE Consortium; RISE Collaborators. Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes. Diabetes Care. 2018 Dec;41(12):2544-2551. doi: 10.2337/dc18-1662. Epub 2018 Oct 3.</citation>
    <PMID>30282699</PMID>
  </results_reference>
  <results_reference>
    <citation>RISE Consortium. Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. Diabetes Care. 2018 Aug;41(8):1696-1706. doi: 10.2337/dc18-0244. Epub 2018 Jun 25.</citation>
    <PMID>29941497</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 4, 2013</study_first_submitted>
  <study_first_submitted_qc>January 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2013</study_first_posted>
  <results_first_submitted>August 28, 2019</results_first_submitted>
  <results_first_submitted_qc>October 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 21, 2019</results_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Thomas Buchanan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>prediabetes</keyword>
  <keyword>obesity</keyword>
  <keyword>gastric banding</keyword>
  <keyword>metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 28, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT01763346/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT01763346/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited from Kaiser Permanente Southern California</recruitment_details>
      <pre_assignment_details>Five participants randomized to metformin and six participants randomized to gastric banding refused to initiate treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>subjects receiving metformin
Metformin: metformin 1000 mg bid</description>
        </group>
        <group group_id="P2">
          <title>Gastric Banding</title>
          <description>subjects receiving LAP-BAND
gastric banding: LAP-BAND</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44">Five subjects who enrolled in the study refused to initiate metformin therapy, thus did not &quot;start&quot;</participants>
                <participants group_id="P2" count="44">Six subjects randomized to gastric banding refused the banding surgery and, thus, did not &quot;start&quot;</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Intervention</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>subjects receiving metformin
Metformin: metformin 1000 mg bid</description>
        </group>
        <group group_id="B2">
          <title>Gastric Banding</title>
          <description>subjects receiving LAP-BAND
gastric banding: LAP-BAND</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hyperglycemic clamp</title>
          <description>data are reported as gemetric mean and 95% confidence interval</description>
          <units>nmol/l adjusted for insulin sensitivity</units>
          <param>Geometric Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.37" lower_limit="2.71" upper_limit="3.35"/>
                    <measurement group_id="B2" value="3.67" lower_limit="3.28" upper_limit="4.1"/>
                    <measurement group_id="B3" value="3.52" lower_limit="2.99" upper_limit="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oral Glucose Tolerance Test</title>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>fasting glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.2" spread="0.8"/>
                    <measurement group_id="B2" value="6.2" spread="0.7"/>
                    <measurement group_id="B3" value="6.2" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-hour glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.5" spread="2.6"/>
                    <measurement group_id="B2" value="10.4" spread="2.7"/>
                    <measurement group_id="B3" value="10.45" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96.1" spread="10.9"/>
                    <measurement group_id="B2" value="97.5" spread="12.2"/>
                    <measurement group_id="B3" value="96.8" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kilograms per meters squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.0" spread="2.9"/>
                    <measurement group_id="B2" value="35.7" spread="2.9"/>
                    <measurement group_id="B3" value="35.53" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1C</title>
          <description>values are given as standard error and not standard deviation</description>
          <units>percent of hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.82" spread="0.06"/>
                    <measurement group_id="B2" value="5.92" spread="0.06"/>
                    <measurement group_id="B3" value="5.87" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Steady State Beta Cell Compensation</title>
        <description>mean plasma C-peptide concentration during clamp steady state, adjusted for mean clamp insulin sensitivity</description>
        <time_frame>24 months</time_frame>
        <population>Participants completing 24-month hyperglycemic clamp</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>subjects receiving metformin
Metformin: metformin 1000 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Gastric Banding</title>
            <description>subjects receiving LAP-BAND
gastric banding: LAP-BAND</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State Beta Cell Compensation</title>
          <description>mean plasma C-peptide concentration during clamp steady state, adjusted for mean clamp insulin sensitivity</description>
          <population>Participants completing 24-month hyperglycemic clamp</population>
          <units>(nmol/L) adjusted for M/I</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01" lower_limit="2.71" upper_limit="3.35"/>
                    <measurement group_id="O2" value="3.19" lower_limit="2.88" upper_limit="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We selected a sample size that would allow detection of an effect size of ~0.6 or greater between gastric band and metformin groups for measures of β-cell function after two years, hypothesizing greater function in the gastric band group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>35 subjects per group provided 80% power to detect an effect size of 0.59, assuming a 2-sided p=0.05, adjustment for baseline measures using ANCOVA, and correlation of 0.5 between baseline and end-study measures.</p_value_desc>
            <method>General Linear Models</method>
            <method_desc>Differences in primary outcomes between groups at 24-months were compared using general linear models with baseline values included as covariates.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Glycemia</title>
        <description>fasting and 2-hour OGTT glucose levels</description>
        <time_frame>24 months</time_frame>
        <population>participants completing 24 months of interventions</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>subjects receiving metformin
Metformin: metformin 1000 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Gastric Banding</title>
            <description>subjects receiving LAP-BAND
gastric banding: LAP-BAND</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemia</title>
          <description>fasting and 2-hour OGTT glucose levels</description>
          <population>participants completing 24 months of interventions</population>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>fasting glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.95" spread="0.11"/>
                    <measurement group_id="O2" value="5.85" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-hour glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.87" spread="0.57"/>
                    <measurement group_id="O2" value="9.92" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Glycemia</title>
        <description>HbA1C</description>
        <time_frame>24 months</time_frame>
        <population>participants completing 24 months of interventions</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>subjects receiving metformin
Metformin: metformin 1000 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Gastric Banding</title>
            <description>subjects receiving LAP-BAND
gastric banding: LAP-BAND</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemia</title>
          <description>HbA1C</description>
          <population>participants completing 24 months of interventions</population>
          <units>percent of hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.84" spread="0.09"/>
                    <measurement group_id="O2" value="5.73" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>subjects receiving metformin
Metformin: metformin 1000 mg bid</description>
        </group>
        <group group_id="E2">
          <title>Gastric Banding</title>
          <description>subjects receiving LAP-BAND
gastric banding: LAP-BAND</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastric band slippage requiring removal</sub_title>
                <description>gastric band slippage requireing removal</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>acalcuous cholecystitis</sub_title>
                <description>Requering gall bladder removal</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastric sleeve surgery</sub_title>
                <description>elective</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <description>requiring fixation, resutling from traffic accident</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Port revision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>stomach pain or discomfort</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>dairrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Lack of energy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Thomas Buchanan</name_or_title>
      <organization>University or Southern California</organization>
      <phone>3234794319</phone>
      <email>buchanan@usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

